Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis.

Ticiana A LealAngela C ArgentoKrish BhadraD Kyle HogarthJulia GrigorievaRachel M HartfieldRobert C McDonaldPhilip D Bonomi

Published in: Current medical research and opinion (2020)

Advanced NSCLC patients classified VSGood have significantly longer OS than those classified VSPoor. The summary effect size for OS HRs around 0.4-0.5 indicates that the expected median survival of those with a VSGood classification is approximately 2-2.5 times as long as those with VSPoor. The robust prognostic performance of the VeriStrat test across various lines of therapy and treatment regimens has clinical implications for treatment shared decision-making and potential for novel treatment strategies.

Keyphrases

advanced non small cell lung cancer
small cell lung cancer
epidermal growth factor receptor
end stage renal disease
deep learning
stem cells
prognostic factors
climate change
patient reported outcomes